PMN Stock Forecast & Price Target

ProMIS Neurosciences is attractive fundamentally because PMN310 is a differentiated oligomer-selective antibody that targets toxic amyloid-beta while sparing plaque, offering a plausible path to efficacy with lower ARIA liability than approved anti-amyloid drugs. The PRECISE-AD Phase 1b interim data in 144 patients showed zero ARIA-E across all genotypes, placebo-like ARIA-H at 4.4%, and encouraging biomarker shifts of -15% in plasma pTau217 and -13.3% in CSF MTBR-tau243, supporting target engagement. Financially, the company reported a 2Q26 net loss of $11.7MM and ended with about $53.4MM in cash, which management says funds operations through 2027, while shares trading below cash/share of $5.96 leave room for upside if the 1Q27 readout confirms efficacy.

ProMIS Neurosciences is viewed cautiously because its lead Alzheimer’s program, PMN310, remains unproven in the clinic while the recent collapse of Acumen’s Sabirnetug underscores how selective toxic oligomer targeting can still fail on cognition despite amyloid biomarker improvement. The stock’s ~70% drop on October 30 versus XBI’s -1% suggests investors are re-rating the whole AβO thesis, and the company’s own assumptions were weakened by a lowered probability of success to 30% from 40% and a higher 11.5% discount rate from 11%. With only a PRECISE-AD Phase 1b readout ahead, heavy competition from approved and emerging Aβ antibodies, and a likely need for dilutive financing before later-stage trials, the risk-reward profile appears unfavorable.